The Exploding Market for ADHD Telehealth Startups

The demand for mental health services has never been higher. Over the past few years, a wave of digital health startups emerged to treat Attention Deficit Hyperactivity Disorder directly through your smartphone. While these companies promised unprecedented access to care, they are now facing severe legal trouble and regulatory crackdowns worldwide.

How the ADHD Telehealth Boom Started

The rapid growth of the online ADHD treatment market can be traced back to March 2020. When the COVID-19 pandemic began, the federal government declared a public health emergency. This declaration temporarily paused key provisions of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008.

Before 2020, this federal law required doctors to see a patient in person at least once before they could prescribe controlled substances like Adderall, Ritalin, or Vyvanse. By suspending this rule, the federal government allowed doctors to diagnose patients and prescribe heavy stimulants entirely over video calls.

Startups immediately seized this opportunity. Companies launched aggressive advertising campaigns on platforms like TikTok and Instagram. They targeted adults who suspected they might have undiagnosed ADHD, using relatable memes and short videos. The marketing worked, driving millions of users to these new platforms seeking quick evaluations.

The Major Players and Their Business Models

Several companies quickly rose to the top of this new market. Cerebral, founded in 2020, grew at an astonishing rate. By late 2021, the company had secured high-profile endorsements (including Olympic gymnast Simone Biles) and reached a valuation of $4.8 billion.

Done Health, another massive player in the space, adopted a highly lucrative subscription model. Patients paid an initial diagnostic fee and then a $79 monthly subscription to maintain access to their clinician and receive ongoing prescriptions. Other startups like Klarity Health and Circle Medical also jumped into the market, offering fast appointments that often lasted 30 minutes or less.

However, the subscription model created deep concerns among medical professionals. Critics argued that tying a company’s financial success to monthly subscriptions incentivized doctors to diagnose ADHD and prescribe medication just to keep paying customers on the platform.

A Catalyst for the Adderall Shortage

The explosive growth of these telehealth platforms had immediate real-world consequences. The sheer volume of prescriptions generated by startups like Cerebral and Done put massive strain on the pharmaceutical supply chain.

In October 2022, the Food and Drug Administration officially announced a nationwide shortage of Adderall. Drug manufacturers, such as Teva Pharmaceuticals, simply could not produce enough generic amphetamine salts to match the sudden spike in demand. This left millions of patients who had relied on these medications for years unable to fill their prescriptions. The supply chain collapse eventually spilled over into alternative ADHD medications like Vyvanse and Concerta.

Global Scrutiny and Major Arrests

The tension between easy access and safe medical practice soon caught the attention of law enforcement. The Department of Justice and the Drug Enforcement Administration launched massive investigations into the prescribing practices of these digital health platforms.

The most significant action occurred in June 2024. The DOJ indicted Ruthia He, the CEO of Done Health, and David Brody, the company’s clinical president. Authorities arrested them on charges of running a $100 million healthcare fraud scheme. The government alleged that they intentionally distributed Adderall over the internet without a legitimate medical purpose.

Cerebral also faced a harsh reckoning. In April 2024, the company agreed to pay over $7 million to settle charges brought by the Federal Trade Commission and the DOJ. The government penalized Cerebral for sharing sensitive patient health data with third-party advertisers and using deceptive cancellation practices to trap customers in subscriptions.

The corporate sector also took action against these startups. Major retail pharmacies, including CVS Health, Walgreens, and Walmart, instructed their pharmacists to block prescriptions coming from Cerebral and Done. Pharmacists grew suspicious of the high volume of maximum-dose stimulants being called in by out-of-state telehealth providers.

This scrutiny is not limited to the United States. In the United Kingdom, a 2023 investigation by the BBC’s Panorama program exposed severe flaws in private online ADHD clinics like Harley Psychiatrists. Undercover journalists received powerful stimulant prescriptions after brief, low-quality video assessments, prompting calls for stricter regulations from the UK government.

What the Future Holds for Telehealth Prescriptions

The regulatory environment for online mental health services remains highly unstable. The DEA initially planned to end the pandemic-era telehealth rules and reinstate the in-person visit requirement for controlled substances in late 2023.

However, after receiving a record-breaking 38,000 public comments from concerned patients and doctors, the DEA backed down. The agency issued a temporary rule extending telehealth prescribing flexibilities through December 31, 2024.

Patients and providers are now waiting for the DEA to announce a permanent set of rules. Industry experts expect the new regulations to feature a hybrid model. This means a patient might be able to get an initial 30-day supply of a stimulant via telehealth, but they will likely need to complete at least one in-person medical evaluation to receive refills.

Frequently Asked Questions

Can I still get ADHD medication through a telehealth startup? Yes. Through December 31, 2024, federal rules still allow doctors to prescribe Schedule II stimulants via telemedicine. However, your local pharmacy might refuse to fill the prescription if it comes from a startup with a controversial track record.

Why was the leadership of Done Health arrested? In June 2024, the Department of Justice indicted Done Health CEO Ruthia He and Clinical President David Brody. The government charged them with healthcare fraud and illegally distributing controlled substances, alleging they ran a $100 million scheme that prioritized profit over patient safety.

What is the Ryan Haight Act? The Ryan Haight Act is a 2008 federal law designed to stop rogue internet pharmacies. It requires a patient to have at least one in-person medical evaluation before a doctor can prescribe a controlled substance. This rule was temporarily suspended during the COVID-19 pandemic.

Did telehealth startups cause the Adderall shortage? While manufacturing delays played a role, the FDA and DEA have both pointed to the massive surge in prescriptions driven by telehealth startups as a primary catalyst for the nationwide stimulant shortage that began in late 2022.